The rise of technology in diabetes care. Not all that is new is necessarily better. by Acerini, Carlo
Pediatric Diabetes 
The rise of technology in diabetes care. Not all that is new is necessarily better.
Abstract
Health-care technologies have brought many benefits to the medical profession and to 
patients. The introduction of the continuous subcutaneous insulin infusion (CSII) pump and 
continuous glucose monitoring (CGM) devices offers patients with Type 1 diabetes (T1D) 
the opportunity to optimise their blood glucose control and are increasingly being 
championed as a routine treatment approach for young people. However, the current 
evidence base does not convincingly support arguments for the generalized application of 
CSII and CGM into routine clinical practice. The ‘patient-medical device interface’ is clearly 
a complex paradigm, and central to its success is the degree of adherence, understanding 
and engagement demonstrated by the patient with the technology. The introduction CSII / 
CGM technologies into the daily routine care of the patient imposes both psychological 
and ‘time-effort’ burdens that many patients and families with T1D will find demanding. The 
current application of these devices cannot therefore be considered a panacea for the self-
management of T1D, and raises a number of challenging problems, including those of a 
practical, health-economic and ethical nature that need to be fully resolved before it and 
other emerging technologies can be considered to have achieved this status.
Introduction 
Health-care technologies have brought many benefits to the medical profession and to 
patients. Indeed, the rise of modern medicine has largely been founded on the introduction 
of innovative technologies, resulting in the more effective diagnosis and management of 
many medical conditions, with consequent improvements in patient quality of life and 
survival. However, these advancements in medical care have not been achieved without 
substantial cost to health-care systems and to society in general (1) (2).  The increased 
use, and reliance, on technology has inevitably resulted in changes to how health-care is 
delivered, raising questions and concerns of an economic and ethical nature (3).  
Moreover, many of the technologies in medicine are widely used without good evidence of 
their safety and efficacy (4). There is also an assumption that ‘high tech’ equates to ‘high 
quality’ and to ‘high priority’ (5); a perspective that is frequently held by patients and the 
public, and which is often driven by a biased section of the health care profession and by 
an increasingly misinformed media. It is therefore not surprising that a general social myth 
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pervades that stipulates that ‘new’ is better than ‘old’, ‘advanced’ better than ‘simple’ and 
that ‘more’ is better than ‘little’ (3).
The above issues are also pertinent to the field of children and young people’s diabetes, 
where, over the last two decades, there have been a plethora of technologies introduced 
into the market pace and into routine clinical practice. Prominent amongst these 
developments have been the introduction of the continuous subcutaneous insulin infusion 
(CSII) pump and continuous glucose monitoring (CGM) systems, devices that are 
increasingly being championed as a routine treatment approach for young people with 
Type 1 diabetes (T1D) by some clinicians and health-care organizations. However, the 
current evidence base does not convincingly support arguments for the generalized 
application of CSII and CGM into routine clinical practice; either from a clinical 
effectiveness point of view, nor from a health-economic and ethical perspective.
Clinical effectiveness - the inconclusive evidence base
Whilst diabetes related technologies such as CSII or CGM (either alone or in combination 
as ‘sensor augmented pump’ (SAP)) are now widely used in many countries, their 
effectiveness in clinical practice has not been consistently demonstrated, and neither is it 
clear which patients are most likely to benefit from it. It is generally accepted that 
comparisons and assessment of clinical effectiveness of medical technologies are 
determined on an ‘evidence based’ basis, relying on data from appropriately designed, and 
sufficiently powered, randomized controlled trials, rather from than observational studies. 
However such an evidence base for CSII and CGM based technologies is rather limited, 
particularly when studies relevant to children and adolescence with diabetes are 
specifically considered. 
When looked at individually, most recent observational studies and published RCTs in 
young people appear to report either small, or modest, improvements in diabetes related 
outcomes, when CSII or CGM are compared against ‘conventional’ approaches to 
diabetes management with multiple daily injection (MDI) regimens (6-9) or with self-
monitoring of blood glucose (SMBG) using portable blood glucose measuring devices 
(10-12). However, when the data from these studies are combined and subjected to a 
systematic review and meta-analyses (SRMA) the same conclusions are not always 
supported. The SRMA is viewed as more powerful and influential in terms of evidence 
gathering and decision-making, with data from RCTs given priority over observational 
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studies. In a meta-analysis of RCTs conducted in patients with T1D (n 15) between 2002 
and 2008, CSII was associated with a slightly lower glycated haemoglobin index ((HbA1c) 
random-effects weighted mean difference, 0.2%; 95% confidence interval (CI), 0.3, 0.10), 
but had no significant effect on either severe or nocturnal hypoglycemia rates, when 
compared to MDI therapy (13).  Similar findings have also been reported in a recent meta-
analysis performed by Yeh and colleagues, who pooled together the data from 33 RCTs 
performed in children or adults with T1D; which compared CSII vs MDI (n 19) , CGM vs 
SMBG (n 10)  or SAP vs MDI + SMBG (n 4) (14). Their results showed that for patients 
with T1D, CSII was no different to MDI therapy in terms of glycemic control; with similar 
reductions in HbA1c levels and hypoglycaemia rates observed between the treatment 
groups. A separate sub-analysis of those RCTs specific to children and adolescent with 
T1D (n 7) did not differ in its conclusions. However, in contrast to these observations there 
was moderate to high strength evidence from RCTs comparing the effectiveness of CGM 
against SMBG to suggest that CGM technology might confer some benefit in terms of 
improved glycemic control (14); but this effect, was dependent on CGM adherence rates 
and was highest in those studies were ’sensor’ adherence was sustained at levels of 60% 
or above (14).
Whilst comparisons of glycemic indices such as HbA1c and hypoglycemia rates are 
usually the primary outcomes of most RCTs, evaluation of patient quality of life (QoL) 
measures are increasingly considered to be of equal importance. It is frequently assumed 
that use of the latest technology is associated with greater satisfaction and contentment 
from a user perspective when compared to conventional treatment methods or use of older 
technology (3). However the evidence base derived from the diabetes setting does not 
convincingly support this common misconception. Low strength evidence from SRMAs 
suggest that CSII might confer improved QoL on patients when compared to MDI therapy, 
whereas CGM does not appear to have any significant impact on patient QoL when 
compared to standard methods of blood glucose monitoring (14). 
However, it is important to acknowledge that even these SRMAs need to be interpreted 
with caution. Firstly, their conclusions may be already out of date given the rapidly 
evolving, new improved devices being introduce into the market. Secondly, SRMAs are 
themselves significantly limited by the poor design quality of the trials included in the 
analyses. The biggest problem is due to the risk of bias resulting from the lack of blinding 
(participants; clinicians and data assessors) and from the incomplete data and selective 
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outcome reporting, which is evident in most of the published trials. For these reasons 
doubt has been cast on whether SRMAs are relevant for clinical and economic decision 
making purposes as they may be significantly underestimating the utility and effectiveness 
of current CSII / CGM systems (15, 16). Alternate ‘decision-making’ based approaches to 
meta-analyses (i.e. through the pre-selection of specific clinical trials based on their 
intended use) have been proposed, yet even when this technique is applied the evidence 
in favour of CSII against conventional MDI is only modestly increased and is of weak 
statistical significance (16).
Observational studies, particularly those utilizing large national / multinational databases, 
should not be discounted. Whilst these types of studies also present a risk of bias, the 
data collected is invariably from over a longer period of time and is more representative of 
a ‘typical’ or ‘standard' clinic population. Studies by the Hvidoere International Study 
Group, found no association between glycaemic control and type of insulin regimen, 
whether analyzed at an individual patient or by center of care level (17). Other national, 
multi-center, databases have reported inconsistent and contrasting observations regarding 
the relationship between type / mode of insulin delivery regime and outcome measures 
such as HbA1c or hypoglycaemia frequency (18) (19) (20). A recent combined analysis of 
data from 3 large national databases suggests that CSII confers improved glycaemic 
control compared to MDI, yet closer scrutiny of the data reveals that this result was almost 
entirely due to the contribution from one of the databases; representing a population with 
traditionally higher background mean HbA1c values (21). This contrasts with the data from 
the other two databases included in this study, where little or no difference in glycaemic 
control was observed between CSII and MDI patients (21). Indeed in keeping with this, 
other observational and RCT studies demonstrate that the greatest effective of either CSII 
is seen in those patients with poorest glycemic control (i.e. highest HbA1c or severest / 
most frequent hypoglycaemia) at baseline (7, 22, 23). Furthermore, under clinical trial 
conditions the greatest benefit of technology use is seen in those patients who adhere 
strictly and engage frequently with treatment regimen requirements. CGM use, either 
independently or directly linked with CSII (as sensor augmented pump (SAP)), delivers its 
greatest benefits in terms of improved HbA1c and hypoglycaemia frequency in those 
patients who actively used CGM monitoring as instructed. Several studies document a 
clear relationship between improved HbA1c and reduced hypoglycaemia frequency with 
the number of days per week of use (24) (25) (26), with greatest benefits seen in those 
who wear and engage with their devices for at least 60 to 70% of the time (14). However, 
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most observational studies reveal that less than half of young people using CGM use their 
device for greater than 70% of the time, and that after one year from onset 41% of patients 
had discontinued using it (25, 27). This suggests that under free-living conditions issues 
regarding the acceptability and utility of CGM appears to be a major hurdle limiting the 
effectiveness of this type of technology. This observation also emphasises the point that 
whatever the type of intervention, diabetes management is primarily dependent on patient 
behaviour and acceptability (28) and that technologies such as CSII and CGM impose an 
increased degree of burden and responsibility that inevitably many patients and families 
struggle to accept and to adhere to over the longer term. Whilst patients perceive diabetes 
technology use to have many positive attributes it is clear that many negative attitudes 
also co-exist (29-31). 
Cost effectiveness  - the health economic uncertainties
The costs of diabetes care have continued to rise inexorably year on year for most 
developed countries (32), with a substantial proportion of this attributable to patients with 
Type 1 diabetes and to the increasing use of technologies such as CSII and CGM. 
Assessment of the cost - benefit of these technologies has therefore become a priority for 
healthcare providers (33) and for the medical insurance industry, who increasingly are 
seeking best value for money. Relatively few studies have been published to date, and 
whilst some recent reports have predicted favourable health-economic outcomes 
associated with the medium to long-term use of CSII, CGM or SAP when compared to 
standard treatment approaches (based on a incremental cost effectiveness ratio threshold 
of $50,000 per quality-adjusted life years) (34-37), others have clearly not (38, 39). This 
inconsistency in cost-effectiveness forecasting is not a surprise given the different 
analytical models used and the projected health-care assumptions made within them. 
Moreover, given the poor quality of clinical trials, and the heterogeneity of the study 
populations included, meaningful prediction of the cost - benefit impacts of these 
interventions are far from certain. Furthermore, the relevance of these health-economic 
analyses to children and young people with diabetes is also questionable due to the fact 
that the background risk factor and disease progression assumptions employed in these 
models are based from observations made in adult populations. Therefore the long-term 
cost-benefits of these technologies to young patients with T1D over other treatment 
approaches remains significantly in doubt, and further questions whether the current trend 
for increased introduction of CSII and CGM into routine practice is justified or represents 
‘good value for money’. 
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Affordability and Access - the financial and ethical constraints 
As health care costs continue to increase can we afford to pay for the widespread usage of 
these technologies? Despite the lack of good evidence, and because of the increasing 
demand by clinicians and patients, many health care organizations and providers have 
been compelled to produce guidance as to who should have access to these technologies 
(40, 41). Yet in most cases this guidance is too general, variably interpreted, and have 
‘selection’ criteria that are not specific enough to identify those patients and families most 
likely to benefit. Furthermore many patients transitioning to the more expensive 
technologies may be already achieving good glycemic control with standard treatment 
approaches. As a result many patients starting or transferring to CSII or CGM fail to 
optimize their diabetes control beyond that achieved with cheaper conventional treatment 
regimens, or are unable to sustain initial improvements over the longer term (42) (27). 
Given the relatively high costs of these technologies this scenario does not represent 
‘good value for money’ and raises a critical ‘affordability’ issue that our increasingly 
financially stretched health care systems cannot ignore. Whether accessed via publicly 
funded or via ‘private’ medical insurance based systems, diabetes technology is set to 
impose a significant financial burden on the individual and on society in general; 
contributing to heath care cost inflation and draining much needed resources from other 
areas of care. This financial burden will inevitably result in inequities in access to 
technology: with those health care providers / systems who can afford not to ration their 
supplies, and those individuals who have the means of paying, gaining access to these 
devices over and above those who cannot. 
Barriers to patient access to technology also exist for other, more complex, discriminatory 
reasons. There is good evidence that were CSII / CGM should be readily available, that 
some patients who would benefit from using these devices do not access them. Clinician 
preference / center bias for other treatment options may be one explanation for this, but 
several studies have revealed that diabetes technology uptake is significantly lower in 
patients from certain racial/ethnic groups, and may be independently influenced by other 
socio-economic (e.g. medical insurance status; household income) and cultural factors 
(21, 43-45). Understanding the reasons for these barriers and overcoming them will be 
important for insuring that patients from low income and from minority groups are not 
discriminated against and are not denied the benefits that technology could bring to some 
of them.
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Conclusions 
Given the current state of the art, and the evidence base available, the assertion that 
relatively complex and costly medical devices should be generalized to the typical patient 
with T1D, delivering ‘superior’ or ‘better’ outcomes over the long-term compared to 
conventional insulin therapy approaches, seems misplaced and unfounded. This is not to 
say that in the future that diabetes related technologies such as CSII and CGM (and more 
advanced integrated systems) will not achieve this status, as there is not doubt that 
technology will evolve and improve, and may even become cheaper and therefore ‘cost-
effective’, with time. Before this goal is achieved significant barriers will need to be 
overcome that not only improves the technical and clinical efficacy of these devices but 
also reduces the significant practical and psychological burdens that the current 
generation of devices impose. In the meantime, as we advance toward that goal, diabetes 
technologies such as CSII and CGM should be targeted to those patients who stand to 
obtain clear benefit over and above that could be achieved with conventional treatment 
approaches. This also means removing the discriminatory barriers that currently seems to 
disadvantage patients belonging to certain ethnic and socio-economic groups. As success 
(in glycaemic terms at least) is highly dependent on human behavior (29, 30), and on the 
degree and durability of engagement with technology over the longer term, it makes sense 
to develop appropriate tools and resources to rationalize the selection (and indeed de-
selection) of patients / families for technology use (46). Furthermore, clinicians must 
remain pragmatic and flexible in their approach to insulin therapy and must not loose sight 
of the alternate approaches available to them. New technologies must also be thoroughly 
and critically assessed with the same rigor as drugs are (47), and health-care workers and 
patients must be equally informed about the uncertainties of their benefits as well as their 
‘hyped’ gains (3). Ultimately treatment regimens should always be individualized and 
diabetes care teams should be focused on achieving glycaemic targets by whatever 
means best suitable to the patient. 
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